AURA
Price
$7.77
Change
+$0.10 (+1.30%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
383.13M
54 days until earnings call
EDIT
Price
$1.23
Change
-$0.01 (-0.81%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
102.36M
40 days until earnings call
Ad is loading...

AURA vs EDIT

Header iconAURA vs EDIT Comparison
Open Charts AURA vs EDITBanner chart's image
Aura Biosciences
Price$7.77
Change+$0.10 (+1.30%)
Volume$1.5K
Capitalization383.13M
Editas Medicine
Price$1.23
Change-$0.01 (-0.81%)
Volume$19.88K
Capitalization102.36M
AURA vs EDIT Comparison Chart
Loading...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AURA vs. EDIT commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a Hold and EDIT is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (AURA: $7.67 vs. EDIT: $1.24)
Brand notoriety: AURA and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURA: 60% vs. EDIT: 52%
Market capitalization -- AURA: $383.13M vs. EDIT: $102.36M
AURA [@Biotechnology] is valued at $383.13M. EDIT’s [@Biotechnology] market capitalization is $102.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $370.67B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURA’s FA Score shows that 1 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • AURA’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, both AURA and EDIT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AURA’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • AURA’s TA Score: 4 bullish, 4 bearish.
  • EDIT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than AURA.

Price Growth

AURA (@Biotechnology) experienced а -2.91% price change this week, while EDIT (@Biotechnology) price change was -7.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.05%. For the same industry, the average monthly price growth was +3.04%, and the average quarterly price growth was -1.59%.

Reported Earning Dates

AURA is expected to report earnings on May 08, 2025.

EDIT is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AURA($383M) has a higher market cap than EDIT($102M). EDIT YTD gains are higher at: -2.362 vs. AURA (-6.691). AURA has higher annual earnings (EBITDA): -91.84M vs. EDIT (-222.63M). EDIT has more cash in the bank: 265M vs. AURA (174M). AURA has less debt than EDIT: AURA (19.1M) vs EDIT (38.5M). EDIT has higher revenues than AURA: EDIT (61.8M) vs AURA (0).
AURAEDITAURA / EDIT
Capitalization383M102M375%
EBITDA-91.84M-222.63M41%
Gain YTD-6.691-2.362283%
P/E RatioN/AN/A-
Revenue061.8M-
Total Cash174M265M66%
Total Debt19.1M38.5M50%
FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AURAEDIT
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
78%
Momentum
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 15 days ago
78%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Ad is loading...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with ABCL. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
-0.78%
ABCL - AURA
54%
Loosely correlated
-0.68%
MGTX - AURA
50%
Loosely correlated
+3.85%
EDIT - AURA
49%
Loosely correlated
+1.64%
ABOS - AURA
48%
Loosely correlated
-5.85%
VRDN - AURA
47%
Loosely correlated
-1.90%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with NTLA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+1.64%
NTLA - EDIT
60%
Loosely correlated
-2.99%
CRSP - EDIT
59%
Loosely correlated
+3.23%
BEAM - EDIT
54%
Loosely correlated
+0.04%
PRME - EDIT
52%
Loosely correlated
+0.35%
MGTX - EDIT
50%
Loosely correlated
+3.85%
More